Monte Rosa Therapeutics (GLUE) Return on Sales [ROS] (2020 - 2026)
Monte Rosa Therapeutics' Return on Sales [ROS] came in at -547.84% for Q2 2026, down 480.78 percentage points from -67.06% a year earlier but up 640.62 percentage points from the prior quarter.
Monte Rosa Therapeutics (GLUE) Return on Sales [ROS] (2020 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Monte Rosa Therapeutics reported Return on Sales [ROS] of -633.04%, down 641.45 percentage points year-over-year; for FY2025, it came in at -43.83%, up 63.43 percentage points from FY2024.
- Going back by year, Return on Sales [ROS] was -107.26% in FY2024.
- The five-year range for quarterly Return on Sales [ROS] is -3284.49% (Q1 2024) to 51.85% (Q1 2025).
- Year-over-year, Return on Sales [ROS] has declined for three consecutive quarters, with an average year-over-year change of +77.32 percentage points over the last six quarters.
- Business Quant data shows GLUE's Return on Sales [ROS] at -1188.46% (Q1 2026), -1787.67% (Q4 2025) and -258.26% (Q3 2025) in the three quarters before Q2 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | 24.35% |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | 28.37% |
| 10 | Monte Rosa Therapeutics | 923.85 Mn | 335.67 Mn | - | -547.84% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -547.84% |
| Mar 31, 2026 | -1,188.46% |
| Dec 31, 2025 | -1,787.67% |
| Sep 30, 2025 | -258.26% |
| Jun 30, 2025 | -67.06% |
| Mar 31, 2025 | 51.85% |
| Dec 31, 2024 | 21.44% |
| Sep 30, 2024 | -287.84% |
| Jun 30, 2024 | -695.25% |
| Mar 31, 2024 | -3,284.49% |
| Sep 30, 2023 | -7,082.26% |
| Jun 30, 2023 | -4,430.23% |
| Mar 31, 2023 | -3,384.26% |
| Dec 31, 2022 | -1,632.61% |
| Sep 30, 2022 | -2,844.73% |
| Jun 30, 2022 | -4,336.15% |
| Mar 31, 2022 | -16,310.07% |
| Dec 31, 2021 | -179,900.00% |
| Sep 30, 2021 | -152,830.77% |
| Jun 30, 2021 | -129,450.00% |
Monte Rosa Therapeutics Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=GLUE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "GLUE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=GLUE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();